What do you think about this (relatively unknown) substance?
![](http://www.longecity.org/images/ImmInstLOGO.gif)
Posted 11 January 2008 - 11:52 PM
Posted 19 January 2008 - 01:19 AM
Posted 10 February 2008 - 05:33 AM
Posted 01 March 2008 - 01:17 AM
Posted 01 March 2008 - 01:19 AM
Posted 01 March 2008 - 03:00 PM
http://www.regenther...dex.jsp?ref=206
Announcements
Colostrinin™ Study Results
11/02/2008
ReGen Therapeutics Plc ('ReGen'or the 'Company') announces that its product Colostrinin™, which is currently marketed in the USA and Australia under the brand name CogniSure™, a nutritional supplement to 'support healthy brain aging and cognition in humans'* has recently been shown to be beneficial and well-tolerated in aging pet cats and dogs with signs of senility and/or cognitive dysfunction.
Open pilot studies, conducted by Cinque Ports Veterinary Associates, Hawkhurst, Kent, UK involved the daily dosing of aged cats and dogs with Colostrinin™ powder sprinkled into their food or drink.
To be eligible for the study, subject animals displayed acknowledged clinical signs of senility and/or cognitive dysfunction. Eighteen cats and twenty-two dogs, each resident in their normal domestic environment, received a daily dose of Colostrinin™ for four months. The clinical condition of each animal was assessed by a veterinary surgeon and the owner completed a questionnaire about aspects of the animal's behaviour at monthly intervals. Results were compared to individual base-line assessments, prior to treatment.
Summarising the study findings Nicholas Mills, Principal Investigator to the study said 'These results clearly show that Colostrinin™ can significantly reduce the symptoms of cognitive dysfunction in aged cats and dogs. That Colostrinin™ was effective was reinforced by the fact that when animals were assessed one month after completion of the study, and having had no Colostrinin™ for one month, most animals showed a worsened condition'.
The study showed Colostrinin™ to be well tolerated. With regard to specific benefits, a number of owners noted improvements in symptoms related to disorientation, sleep and grooming. A significant proportion of owners reported an increase in appetite, water consumption and an improvement in coat condition.
Percy Lomax, Chairman and Chief Executive Officer of ReGen said 'These results show a potential benefit for aging cats and dogs and we are entering into discussions with potential licensees. The full results are being written up with a view to publication in a peer-eviewed veterinary journal'.
* Colostrinin™ for use as a human nutraceutical is licensed in North America and Australasia to Metagenics Inc. of San Clemente, California (www.Metagenics.com). Discussions are ongoing with potential distributors in other regions of the world.
Notes for Editors:
Cognitive dysfunction in cats and dogs:
The increasing awareness of Alzheimer's disease and senile dementia in humans has in recent years resulted in the owners of companion animals being more aware of their animals suffering from similar cognitive dysfunction. This has probably been aided by advances in veterinary medicine resulting in a greater number of healthy animals and an increased life expectancy both of which will have helped increase the number of animals showing symptoms of cognitive dysfunction (Gunn-Moore et al. 2006).
Dogs have been known to suffer from cognitive dysfunction for some time and have become an accepted model for the study of related conditions in humans (e.g. Cummings et al. 1996 & Studzinski et al. 2006). It is only relatively recently that cats have been suggested to suffer from a condition akin to Alzheimer's disease (Gunn-Moore et al. 2006), characterised by ss-amyloid and AT8 immunoreactive phosphoryated tau deposits.
Figures for the prevalence of age related behavioural problems suggest that 28% of dogs aged 11-12 show at least one symptom. This rises to 65% in the 12-16 years age group (Neilson et al. 2001). The situation would appear to be similar in cats where 28% of animals aged 11-14 show at least one symptom; rising to more than 50% of cats aged 15 years or more (Gunn-Moore et al. 2006).
Whilst some drugs have been useful in the treatment of dementia related symptoms caused by a decrease in blood supply to the brain, there is no treatment currently available to deal directly with Alzheimer-like pathologies in companion animals.
For further information:
Percy Lomax
ReGen Therapeutics Plc
Tel No 7153 4920
Roland Cornish/Felicity Geidt
Beaumont Cornish Limited
Tel No 020 7628 3396
Posted 26 May 2008 - 10:54 AM
Posted 26 May 2008 - 10:58 AM
Posted 29 May 2008 - 09:49 PM
Posted 23 August 2010 - 10:25 PM
Posted 22 September 2010 - 10:18 AM
0 members, 1 guests, 0 anonymous users